Alpine Immune Sciences, Inc.

NasdaqGM:ALPN Stok Raporu

Piyasa değeri: US$4.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Alpine Immune Sciences Yönetim

Yönetim kriter kontrolleri 3/4

Alpine Immune Sciences CEO'su Mitch Gold, Jun2016 tarihinde atandı, in görev süresi 7.92 yıldır. in toplam yıllık tazminatı $ 2.92M olup, şirket hissesi ve opsiyonları dahil olmak üzere 20.5% maaş ve 79.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.019% ine doğrudan sahiptir ve bu hisseler $ 860.60K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 6.1 yıldır.

Anahtar bilgiler

Mitch Gold

İcra Kurulu Başkanı

US$2.9m

Toplam tazminat

CEO maaş yüzdesi20.51%
CEO görev süresi7.9yrs
CEO sahipliği0.02%
Yönetim ortalama görev süresi4.3yrs
Yönetim Kurulu ortalama görev süresi6.1yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Apr 11

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Summary Vertex Pharmaceuticals Incorporated is acquiring Alpine Immune Sciences, Inc. for $4.9 billion in cash to obtain the use of povetacicept for IgAN and other kidney disorders. Positive results of povetacicept for treatment of patients with IgAN were first revealed at ASN Kidney Week In November 2023, with additional positive data just released the other day. Povetacicept is also being explored in RUBY-4 study targeting patients with autoimmune cytopenias; Data from this study will be released at a medical meeting in the 1st half of 2024. A phase 2 trial initiation, using povetacicept for the treatment of patients with systemic lupus erythematosus, is expected in the 2nd half of 2024. Read the full article on Seeking Alpha
Analiz Makalesi • Mar 21

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) investors will be delighted, with the company turning in some strong...
Analiz Makalesi • Mar 20

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Alpine...
Seeking Alpha • Mar 07

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Summary Alpine Immune Sciences has discarded two drug candidates since joining the Nasdaq in 2027, but its stock price has risen >200% in six months owing to its latest lead candidate. Povetacicept has shown promising results in a Phase 2 study for the treatment of IgA nephropathy, with significant reductions in proteinuria and disease-related biomarkers. The market potential for povetacicept in the IgA nephropathy indication alone is estimated to be worth billions of dollars, making it a potentially lucrative asset for Alpine. There's plenty of competition in the IgAN space, however, including two recently approved drugs and two pipeline assets with the same MoA as povetacicept. These assets belong to Vera Therapeutics and Novartis, and it's difficult to pick a winning candidate, albeit Alpine's is the least advanced. As such, I'm not sure the company fully justifies its $2.5bn market cap - I'm on the sidelines until more data is shared. Read the full article on Seeking Alpha
Analiz Makalesi • Feb 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Despite an already strong run, Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shares have been powering on, with a gain...
Analiz Makalesi • Dec 19

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Despite an already strong run, Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shares have been powering on, with a gain...
Analiz Makalesi • Sep 23

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • May 11

Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

With a median price-to-sales (or "P/S") ratio of close to 11.6x in the Biotechs industry in the United States, you...
Analiz Makalesi • Dec 12

Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Sep 20

Alpine Immune Sciences drops 13% after hours on $100M stock offering

Alpine Immune Sciences (NASDAQ:ALPN) stock dropped 13% after the bell on Tuesday after the firm announced an underwritten public offering of $100M of shares and pre-funded warrants to buy stock. Underwriters will be granted an option for 30 days to buy up to an additional $15M of shares at the offering price. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms.
Analiz Makalesi • Aug 09

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Apr 25

Alpine: Rest Before Rallying Again

Implementing an appropriate strategy would capture the most profits. One such strategy is diversification. A promising stock for your portfolio to diversify is Alpine Immune Science. As a rising leader in immuno-oncology, Alpine has great medicines and has thus been able to secure three interesting partnerships. Despite not having much further catalyst this year, the company is set to release data of a Phase 1 trial studying ALPN303 by mid-year.
Analiz Makalesi • Apr 12

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analiz Makalesi • Sep 18

Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analiz Makalesi • Aug 18

Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Celebrations may be in order for Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shareholders, with the analysts...

CEO Tazminat Analizi

Mitch Gold'un ücretlendirmesi Alpine Immune Sciences'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$3mUS$599k

-US$32m

Sep 30 2023n/an/a

-US$57m

Jun 30 2023n/an/a

-US$59m

Mar 31 2023n/an/a

-US$64m

Dec 31 2022US$3mUS$544k

-US$58m

Sep 30 2022n/an/a

-US$54m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$47m

Dec 31 2021US$3mUS$523k

-US$50m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$33m

Dec 31 2020US$1mUS$500k

-US$28m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$33m

Mar 31 2020n/an/a

-US$35m

Dec 31 2019US$2mUS$485k

-US$42m

Sep 30 2019n/an/a

-US$47m

Jun 30 2019n/an/a

-US$48m

Mar 31 2019n/an/a

-US$44m

Dec 31 2018US$1mUS$400k

-US$36m

Sep 30 2018n/an/a

-US$30m

Jun 30 2018n/an/a

-US$15m

Mar 31 2018n/an/a

-US$11m

Dec 31 2017US$2mUS$300k

-US$8m

Tazminat ve Piyasa: Mitch 'nin toplam tazminatı ($USD 2.92M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 7.03M ).

Tazminat ve Kazançlar: Mitch şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Mitch Gold (55 yo)

7.9yrs
Görev süresi
US$2,921,224
Tazminat

Dr. Mitchell H. Gold, also known as Mitch, M.D., has been Executive Chairman and Chief Executive Officer at Alpine Immune Sciences Inc. since January 2015 and June 2016 respectively. Dr. Gold served as the...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Mitchell Gold
Executive Chairman & CEO7.9yrsUS$2.92m0.019%
$ 860.6k
Stanford Peng
President and Head of Research & Development5.1yrsUS$1.75m0.43%
$ 19.2m
Paul Rickey
Senior VP7.1yrsUS$1.28mVeri yok
Ulrich Fuhs
VP of Finance & Chief Accounting Officerless than a yearVeri yok0.044%
$ 2.0m
M. Yi
Chief Technology Officerless than a yearVeri yokVeri yok
Michelle Greenblatt
Director of Investor Relations & Corporate Communicationsno dataVeri yokVeri yok
Remy Durand
Chief Business Officer4.3yrsVeri yok0.15%
$ 6.6m
Andrew Sandler
Chief Medical Officer1.8yrsVeri yokVeri yok
4.3yrs
Ortalama Görev Süresi
52yo
Ortalama Yaş

Deneyimli Yönetim: ALPN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Mitchell Gold
Executive Chairman & CEO9.3yrsUS$2.92m0.019%
$ 860.6k
Robert Conway
Independent Director6.8yrsUS$110.21k0.073%
$ 3.2m
James Topper
Independent Director7.9yrsUS$101.46k0%
$ 0
Peter Thompson
Independent Director7.9yrsUS$103.96k0%
$ 0
Rafi Ahmed
Member of Scientific Advisory Board5.5yrsVeri yokVeri yok
Xiangmin Cui
Independent Director5.3yrsUS$100.21k0%
$ 0
Andrew Scharenberg
Scientific Advisory Board Chairmanno dataVeri yokVeri yok
Christopher Peetz
Independent Director6.1yrsUS$98.96k0.0028%
$ 123.5k
John Thompson
Member of Scientific Advisory Board5.5yrsVeri yokVeri yok
Manish Butte
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Paul Tumeh
Member of Scientific Advisory Boardno dataVeri yokVeri yok
James Welsh
Member of Scientific Advisory Board5.5yrsVeri yokVeri yok
6.1yrs
Ortalama Görev Süresi
58yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: ALPN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.1 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2024/05/21 02:35
Gün Sonu Hisse Fiyatı2024/05/17 00:00
Kazançlar2024/03/31
Yıllık Kazançlar2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Alpine Immune Sciences, Inc. 14 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Gao Yi ChenBerenberg
Vamil DivanGuggenheim Securities, LLC
Joseph PantginisH.C. Wainwright & Co.